Analysts See $-0.10 EPS for Sophiris Bio, Inc. (SPHS)

March 14, 2018 - By Ellis Scott

 Analysts See $ 0.10 EPS for Sophiris Bio, Inc. (SPHS)
Investors sentiment decreased to 0.64 in 2017 Q3. Its down 1.96, from 2.6 in 2017Q2. It turned negative, as 6 investors sold Sophiris Bio, Inc. shares while 5 reduced holdings. 3 funds opened positions while 4 raised stakes. 1.63 million shares or 1.31% less from 1.65 million shares in 2017Q2 were reported.
Guggenheim Capital Limited invested in 0% or 10,975 shares. Vanguard Group Inc holds 776,205 shares. Citadel Advsr Limited Liability Co holds 36,721 shares or 0% of its portfolio. Wells Fargo & Mn stated it has 1,800 shares or 0% of all its holdings. Royal Bankshares Of Canada invested in 0% or 6,811 shares. Geode Capital Mgmt Ltd stated it has 19,042 shares. Morgan Stanley reported 5,000 shares. B T Cap Mgmt Dba Alpha Cap Mgmt stated it has 10,128 shares. Virtu Financial Lc accumulated 34,671 shares or 0% of the stock. Sabby Mngmt Llc, a New Jersey-based fund reported 333,641 shares. Lpl Financial Limited Liability has 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS). Cetera Advisor Netwr Lc invested 0% of its portfolio in Sophiris Bio, Inc. (NASDAQ:SPHS). Blackrock Incorporated accumulated 75,895 shares or 0% of the stock. Bank & Trust Of America De reported 3,338 shares. Edge Wealth Management Ltd Limited Liability Company, New York-based fund reported 2,000 shares.

Analysts expect Sophiris Bio, Inc. (NASDAQ:SPHS) to report $-0.10 EPS on March, 26.They anticipate $0.03 EPS change or 42.86 % from last quarter’s $-0.07 EPS. After having $-0.11 EPS previously, Sophiris Bio, Inc.’s analysts see -9.09 % EPS growth. The stock decreased 1.87% or $0.04 during the last trading session, reaching $2.1. About 91,722 shares traded. Sophiris Bio, Inc. (NASDAQ:SPHS) has risen 192.94% since March 14, 2017 and is uptrending. It has outperformed by 176.24% the S&P500.

Sophiris Bio, Inc. (NASDAQ:SPHS) Ratings Coverage

Among 6 analysts covering Sophiris Bio (NASDAQ:SPHS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sophiris Bio had 11 analyst reports since August 30, 2016 according to SRatingsIntel. H.C. Wainwright maintained Sophiris Bio, Inc. (NASDAQ:SPHS) on Friday, June 9 with “Buy” rating. The firm earned “Buy” rating on Friday, September 15 by H.C. Wainwright. The firm earned “Buy” rating on Friday, November 10 by H.C. Wainwright. Maxim Group maintained the stock with “Buy” rating in Thursday, June 8 report. The firm has “Overweight” rating by Piper Jaffray given on Tuesday, August 30. As per Wednesday, January 17, the company rating was maintained by H.C. Wainwright. Maxim Group maintained the shares of SPHS in report on Monday, August 14 with “Buy” rating. The rating was initiated by TH Capital with “Buy” on Thursday, September 15. The stock of Sophiris Bio, Inc. (NASDAQ:SPHS) has “Buy” rating given on Thursday, September 15 by Roth Capital. The stock has “Buy” rating by H.C. Wainwright on Friday, August 11.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company has market cap of $63.23 million. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia , as well as for the treatment of localized low to intermediate risk prostate cancer. It currently has negative earnings. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate.

More notable recent Sophiris Bio, Inc. (NASDAQ:SPHS) news were published by: which released: “Sophiris Bio Reports Successful Results from Completed Phase 2a Study of …” on June 09, 2016, also with their article: “Sophiris Bio Inc. SPHS (US: Nasdaq)” published on August 10, 2013, published: “Sophiris Bio: How Far Off Is Topsalysin’s FDA Application?” on October 10, 2016. More interesting news about Sophiris Bio, Inc. (NASDAQ:SPHS) were released by: and their article: “Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint” published on November 10, 2015 as well as‘s news article titled: “Sophiris Bio Secures up to $10 Million in Term Loans from Silicon Valley Bank” with publication date: September 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: